摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Hydrazinyl-2-pyridin-2-ylpyrimidin-4-amine | 1014720-80-9

中文名称
——
中文别名
——
英文名称
6-Hydrazinyl-2-pyridin-2-ylpyrimidin-4-amine
英文别名
——
6-Hydrazinyl-2-pyridin-2-ylpyrimidin-4-amine化学式
CAS
1014720-80-9
化学式
C9H10N6
mdl
——
分子量
202.219
InChiKey
GMGPQMCVCODMHW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    103
  • 氢给体数:
    3
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-Hydrazinyl-2-pyridin-2-ylpyrimidin-4-amine乙酰丙酮 反应 2.0h, 以72%的产率得到6-(3,5-二甲基-吡唑-1-基)-2-吡啶-2-基-嘧啶-4-基胺
    参考文献:
    名称:
    2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A2A antagonists with reduced hERG liability
    摘要:
    In this report, the design and synthesis of a series of pyrimidine based adenosine A(2A) antagonists are described. The strategy and outcome of expanding SAR exploration to attenuate hERG and improve selectivity over A(1) are discussed. Compound 33 exhibited excellent potency, selectivity over A1, and reduced hERG liability. (c) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.01.036
  • 作为产物:
    描述:
    2-(2-吡啶基)-6-氯-4-氨基嘧啶 作用下, 以 乙醇 为溶剂, 反应 4.0h, 以80%的产率得到6-Hydrazinyl-2-pyridin-2-ylpyrimidin-4-amine
    参考文献:
    名称:
    2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A2A antagonists with reduced hERG liability
    摘要:
    In this report, the design and synthesis of a series of pyrimidine based adenosine A(2A) antagonists are described. The strategy and outcome of expanding SAR exploration to attenuate hERG and improve selectivity over A(1) are discussed. Compound 33 exhibited excellent potency, selectivity over A1, and reduced hERG liability. (c) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.01.036
点击查看最新优质反应信息

文献信息

  • 2-Amino-<i>N</i>-pyrimidin-4-ylacetamides as A<sub>2A</sub> Receptor Antagonists: 1. Structure−Activity Relationships and Optimization of Heterocyclic Substituents
    作者:Deborah H. Slee、Yongsheng Chen、Xiaohu Zhang、Manisha Moorjani、Marion C. Lanier、Emily Lin、Jaimie K. Rueter、John P. Williams、Sandra M. Lechner、Stacy Markison、Siobhan Malany、Mark Santos、Raymond S. Gross、Kayvon Jalali、Yang Sai、Zhiyang Zuo、Chun Yang、Julio C. Castro-Palomino、María I. Crespo、Maria Prat、Silvia Gual、José-Luis Díaz、John Saunders
    DOI:10.1021/jm701185v
    日期:2008.3.1
    Previously we have described a novel series of potent and selective A(2A) receptor antagonists (e.g., 1) with excellent aqueous solubility.(1) While these compounds are efficacious A(2A) antagonists in vivo, the presence of an unsubstituted furyl moiety was a cause of some concern. In order to avoid the potential metabolic liabilities that could arise from an unsubstituted fury] moiety, an optimization effort was undertaken with the aim of replacing the unsubstituted furan with a more metabolically stable group while maintaining potency and selectivity. Herein, we describe the synthesis and SAR of a range of novel heterocyclic systems and the successful identification of a replacement for the unsubstituted furan moiety with a methylfuran or thiazole moiety while maintaining potency and selectivity.
  • 2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A2A antagonists with reduced hERG liability
    作者:Manisha Moorjani、Xiaohu Zhang、Yongsheng Chen、Emily Lin、Jaimie K. Rueter、Raymond S. Gross、Marion C. Lanier、John E. Tellew、John P. Williams、Sandra M. Lechner、Siobhan Malany、Mark Santos、Paddi Ekhlassi、Julio C. Castro-Palomino、Marı´a I. Crespo、Maria Prat、Silvia Gual、José-Luis Díaz、John Saunders、Deborah H. Slee
    DOI:10.1016/j.bmcl.2008.01.036
    日期:2008.2
    In this report, the design and synthesis of a series of pyrimidine based adenosine A(2A) antagonists are described. The strategy and outcome of expanding SAR exploration to attenuate hERG and improve selectivity over A(1) are discussed. Compound 33 exhibited excellent potency, selectivity over A1, and reduced hERG liability. (c) 2008 Elsevier Ltd. All rights reserved.
查看更多